Inflamacija niskog stepena i medijatori inflamacije kod osoba sa predijabetesom

  • Dejan M. Marinković Military Medical Academy, *Clinic for Endocrinology, Belgrade, Serbia; †University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Tamara Dragović Military Medical Academy, *Clinic for Endocrinology, Belgrade, Serbia; †University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Ivan Stanojević University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Predrag V. Djurić University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Bratislav Dejanović Institute for Medical Biochemistry, Belgrade, Serbia
  • Jelena Rakočević University of Belgrade, Faculty of Medicine, Institute for Histology and Embryology “Aleksandar Đ. Kostić”, Belgrade, Serbia
  • Saša Kiković Military Medical Academy, Clinic for Endocrinology, Belgrade, Serbia
  • Dragana Malović Military Medical Academy, Clinic for Endocrinology, Belgrade, Serbia
  • Ivana Stevanović Military Medical Academy, Institute for Medical Research, Belgrade, Serbia †University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia;
  • Petar Ristić Military Medical Academy, Clinic for Endocrinology, Belgrade, Serbia
  • Marijana Petrović University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Zoran Lj. Hajduković Military Medical Academy, Clinic for Endocrinology, Belgrade, Serbia
DOI: https://doi.org/10.2298/VSP240328056M
Ključne reči: biomarkeri;, glukoza u krvi;, dijabetes melitus, tip 2;, predijabetes.

Sažetak


Uvod/Cilj. Predijabetes je stanje povišene vrednosti glukoze u krvi (hiperglikemije) ali nedovoljno visoke da bi se postavila dijagnoza dijabetes melitus tipa 2 (DMT2).  Ovo stanje često prethodi pojavi DMT2. Povezanost razvoja ranog poremećaja glikoregulacije sa stanjem hronične upale niskog intenziteta još uvek nije dovoljno dobro shvaćeno. Cilј rada bio je da se ispitaju vrednosti različitih medijatora zapaljenja i biomarkera kod osoba sa predijabetesom. Metode. Opservacionom studijom preseka obuhvaćeno je 60 ispitanika, podeljenih u dve grupe: grupu od 31 bolesnika sa predijabetesom (PDG) i kontrolnu grupu (KG) od 29 zdravih osoba. Serumske vrednosti sedam izabranih citokina/biomarkera su upoređivane između dve grupe ispitanika. Ispitivani su biomarkeri: interleukin (IL)-1β, IL-6, IL-8, IL-18, faktor nekroze tumora (tumor necrosis factor – TNF)-α, E-selektin i faktor rasta vaskularnog endotela (vascular endothelial growth factor – VEGF)-A. Takođe, između ove dve grupe upoređivani su i indeks telesne mase (ITM), obim struka (OS), krvni pritisak (KP), trigliceridi (TG) u serumu, glukoza u plazmi (GP) natašte i glikozilirani hemoglobin (HbA1c). Rezultati. Bolesnici iz PDG imali su statistički značajno više vrednosti TNF-α u poređenju sa ispitanicima KG (73 pg/mL vs. 55 pg/mL, p = 0,024). Registrovan je trend viših nivoa IL-8 i IL-1β i nižih nivoa E-selektina, VEGF-A i IL-18 kod bolesnika iz PDG, ali bez statističke značajnosti. Takođe, bolesnici iz PDG imali su više vrednosti ITM, OS, sistolnog KP, serumskih TG, GP natašte i HbA1c, u poređenju sa ispitanicima KG. Zaključak. Rezultati našeg istraživanja ukazuju na značaj inflamacije i pojedinih medijatora inflamacije u patogenezi ranog poremećaja glikoregulacije. Verujemo da bi ključni cilj budućih istraživanja trebalo da bude usmeren na anti-inflamacijsku terapiju u predijabetesu.

Reference

Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet 2012; 379(9833): 2279–90.

ADA, Standards of Medical Care in Diabetes-2020. Clin Diabetes 2020; 38(1): 10–38.

Nadeem A, Mumtaz S, Naveed AK, Aslam M, Siddiqui A, Lodhi GM, et al. Gene-gene, geneenvironment, gene-nutrient interactions and single nucleotide polymorphisms of inflammatory cytokines. World J Diabetes. 2015; 6(4): 642–47.

Wang Z, Shen XH, Feng WM, Ye G, Qiu W, Li B. Analysis of Inflammatory Mediators in Prediabetes and Newly Diagnosed Type 2 Diabetes Patients. J Diabetes Res 2016; 2016: 7965317. doi:10.1155/2016/7965317

Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373(9682): 2215–21.

Saxena M, Srivastava N, Banerjee M. Association of IL6, TNF-α and IL-10 gene polymorphisms with type 2 diabetes mellitus. Mol Biol Rep 2013; 40: 6271-79.

Brahimaj A, Ligthart S, Ghanbari M, Arfan Ikram M, Hofman A, Franco OH, et al. Novel inflammatory markers for incident pre-diabetes and type 2 diabetes: the Rotterdam Study. Eur J Epidemiol 2017; 32: 217–226.

Grossmann V, Schmitt VH, Zeller T, Panova-Noeva M, Schulz A, Laubert-Reh D, et al. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care 2015; 38: 1356-1364.

Wang М, Li Y, Li S, Lv J. Endothelial Dysfunction and Diabetic Cardiomyopathy. Front Endocrinol 2022; 13: 851941. doi: 10.3389/fendo.2022.851941

Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116(7): 1793–801. This paper links low-grade inflammation with insulin resistance in type 2 diabetes.

Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999; 353(9165): 1649–52.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286(3): 327–34.

Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A,et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003; 52(7): 1799–805.

Garcia C, Feve B, Ferre P, Halimi S, Baizri H, Bordier L, et al. Diabetes and inflammation: fundamental aspects and clinical implications. Diabetes Metab 2010; 36(5): 327–38.

Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98–107.

Maschirow L, Khalaf K, Al-Aubaidy HA, Jelinek HF. Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes - biomarkers as a possible tool for early disease detection for rural screening. Clin Biochem 2015; 48: 581-585.

Weaver JR, Odanga JJ, Breathwaite EK, Treadwell ML, Murchinson AC, Walters G, et all. An increase in inflammation and islet dysfunction is a feature of prediabetes. Diabetes Metab Res Rev 2021; 37(6): e3405. https://doi.org/10.1002/dmrr.3405

Gupta S, Maratha A, Natarajan A, Miggin S, Hoashi S. Analysis of Inflammatory Cytokines in Pre-Diabetic Subjects. Curr Res Diabetes Obes J 2017; 4(5): 555647. DOI: 10.19080/CRDOJ.2017.04.555647

Cruz NG, Sousa LP, Sousa MO, Pietrani NT, Fernandes AP, Gomes KB. The linkage between inflammation and Type 2 diabetes mellitus. Diabetes Res Clin Pract 2013; 99: 85–92.

Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabák AG, Schloot NC, et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009; 32: 421–423.

King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008; 79: 1527–1534.

Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 2012; 14: R141. doi: 10.1186/ar3874

Marques-Vidal P, Bastardo F, Von Kanel R, Paccaud F, Preisig M,Waeber G, Vollenweider P. Association between circulating cytokine levels, diabetes and insulin resistance in a population-based sample (CoLaus study). Clin Endocrinol 2013; 78: 232–241.

Tangvarasittichai S, Pongthaisong S, Tangvarasittichai O. Tumor necrosis factor-Α, interleukin-6, C-reactive protein levels and insulin resistance associated with type 2 diabetes in abdominal obesity women. Indian J Clin Biochem 2016; 31(1): 68–74. doi: 10.1007/s12291-015-0514-0.

Guzman-Flores JM, Munoz-Valle JF, Sanchez-Corona J, Cobian JG, Medina-Carrillo L, Garcia-Zapien AG, et al. Tumor necrosis factor-alpha gene promoter −308G/A and −238G/A polymorphisms in Mexican patients with type 2 diabetes mellitus. Disease Markers 2011; 30: 19–24.

Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52(3): 812-817.

Akash MS, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem 2018; 119: 105-110.

Vilahur G, Ben-Aicha S, Badimon L. New insights into the role of adipose tissue in thrombosis. Cardiovasc Res 2017; 113: 1046-1054.

Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, Al-Abri S, Al-Lawati J, Al-Maskari M. Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol 2013; 2013: 976810. https://doi.org/10.1155/2013/976810

Shu YN, Dong LH, Li H, Pei QQ, Miao SB, Zhang F, et al. CKII-SIRT1-SM22 alpha loop evokes a self-limited inflammatory response in vascular smooth muscle cells. Cardiovasc Res 2017; 113: 1198-1207.

Jansen T, Kroller-Schon S, Schonfelder T, Foretz M, Viollet B, Daiber A, et al. Alpha1AMPK deletion in myelomonocytic cells induces a pro-inflammatory phenotype and enhances angiotensin IIinduced vascular dysfunction. Cardiovasc Res 2018; 114: 1883-1893.

Chou CH, Hung CS, Liao CW, Wei LH, Chen CW, Shun CT, et al. IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res 2018; 114: 690-702.

Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 1997; 82: 4167-4170.

Stith RD, Luo J. Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock 1994; 44: 210-215.

Tiftikcioglu BI, Duksal T, Bilgin S, Kose S, Zorlu Y. Association between the levels of IL-6, sE-selectin and Distal sensory nerve conduction studies in patients with prediabetes. Eur Neurol 2016; 75: 124-131.

Colak A, Akinci B, Diniz G, Turkon H, Ergonen F, Yalcin H, et al. Postload hyperglycemia is associated with increased subclinical inflammation in patients with prediabetes. Scand J Clin Lab Invest 2013; 73(5): 422-427.

He Q, Dong M, Pan Q, Wang X, Guo L. Correlation between changes in inflammatory cytokines and the combination with hypertension in patients with type 2 diabetes mellitus. Minerva Endocrinol. 2019; 44(3): 252-258. doi:10.23736/S0391-1977.18.02822-5.

Sari MI, Tala ZZ, Wahyuni DD. Association between Glycated Hemoglobin with the Levels of Serum Proinflammatory Cytokines and Antioxidants in Patients with Type 2 Diabetes Mellitus in Universitas Sumatera Utara Hospital. Open Access Maced J Med Sci. 2019; 7(5): 715-720.

Williams A, Greene N, Kimbro K. Increased circulating cytokine levels in African American women with obesity and elevated HbA1c. Cytokine. 2020; 128:154989.

Objavljeno
2024/09/30
Broj časopisa
Vol. 81 Br. 09 (2024): Vojnosanitetski pregled
Rubrika
Originalni članak